Evidence map›Paper›PMID 30514386›Full record

ReviewJournal for immunotherapy of cancer2018

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

Michael M Boyiadzis, Madhav V Dhodapkar, Renier J Brentjens, James N Kochenderfer, Sattva S Neelapu, Marcela V Maus, David L Porter, David G Maloney, Stephan A Grupp, Crystal L Mackall and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal for immunotherapy of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michael M BoyiadzisUniversity of Pittsburgh, Pittsburgh, PA, USA.
Madhav V DhodapkarWinship Cancer Institute, Emory University, Atlanta, GA, USA.
Renier J BrentjensDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
James N KochenderferExperimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD, USA.
Sattva S NeelapuDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Marcela V MausMassachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
David L PorterPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
David G MaloneyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Stephan A GruppPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Crystal L MackallCancer Immunology and Immunotherapy Program, Stanford University, Stanford, CA, USA.
Carl H JunePerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Michael R BishopSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA. mbishop@medicine.bsd.uchicago.edu.ORCID 0000-0001-6708-1536

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.P01CA214278 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARL H. JUNE · 2017 to 2026
$26.8M
New Chimeric Antigen Receptors for Treating Hematologic MalignanciesZIABC011417 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOCHENDERFER, JAMES · 2011 to 2025
$8.3M
NCI NIH HHS P01 CA214278NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.

Indexed as

Immunotherapy, AdoptiveAnimalsAntigens, NeoplasmClinical Trials as TopicGenetic EngineeringHematologic NeoplasmsHumansReceptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesTreatment OutcomeAntigens, NeoplasmReceptors, Antigen, T-CellReceptors, Chimeric AntigenAxicabtagene ciloleucelChimeric antigen receptorLeukemiaLymphomaTisagenlecleucel

Identifiers

PMID30514386
PMCPMC6278156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.